{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-385881","form_type":"8-K","ticker":"KURA","cik":"0001422143","company_name":"Kura Oncology, Inc.","filed_at":"2026-09-09T11:05:05+00:00","discovered_at":"2026-09-09T11:10:00.375228+00:00","generated_at":"2026-09-09T11:10:06.383991+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Kura Oncology raises $50M for diabetes-focused subsidiary Caspian; retains ~49% stake","bullets":["Caspian Therapeutics, a new wholly owned subsidiary, raised $50.0M in Series A preferred stock on Sept 8, 2026.","Kura invested $4.3M; post-financing Kura holds ~49.2% of Caspian's outstanding capital stock.","Kura contributed rights to next-gen menin inhibitors for diabetes/cardiometabolic diseases, incl. KO-7246, to Caspian.","Kura granted Caspian non-exclusive licenses to ziftomenib-related patents/data; received reciprocal license for R&D.","Caspian solely responsible for development/regulatory/commercialization in diabetes field; Kura provides services under agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-385881","json":"https://secwatch.observer/filing/0001193125-26-385881.json","markdown":"https://secwatch.observer/filing/0001193125-26-385881.md","text":"https://secwatch.observer/filing/0001193125-26-385881.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1422143/000119312526385881/0001193125-26-385881-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1422143/000119312526385881/d496500d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-09T11:10:06.383991+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}